Posted on 01/13/2024 11:50:27 AM PST by ChicagoConservative27
Forget the fondue.
Caviar, magic mushrooms, gold-leaf desserts, A-list selfies, $2,500-per-night hookers and secret dinners are likely to be on the menu as scores of private jets touch down in Switzerland as soon as Sunday to bring the world’s elite to the small Alpine resort town of Davos for what’s officially known as The World Economic Forum 2024.
(Excerpt) Read more at nypost.com ...
Concerts? Is that what they're calling private A-List activities this year?
Last year:
Be there or be square
Tell the $5000 night hookers to get out of town. Then nuke’em from orbit. It’s the only way to be sure.
As for dealing with us riff-raff, this solution will have a more salubrious effect on the Davos crowd than will all their global prostitutes:
“1.5. Insect Cell-Based Vaccines
Insect cell systems have been widely adopted because of their capacity to produce high levels of proteins and to perform cotranslational and posttranslational modifications, including glycosylation, phosphorylation, and protein processing. This expression platform allows for generation of stable transformed cell lines or transient expression driven by recombinant baculovirus infection. The baculovirus-insect cell expression system, referred to as BEVS, is one of the most well-known and used systems for large-scale production of complex proteins and, most recently, for the development of subunit vaccines [57]. To date, there are three commercially available vaccines produced in insect cells for different indications: Cervarix (GSK) for cervical cancer, Flublok (Protein Sciences, now owned by Sanofi Pasteur) for influenza, and PROVENGE (Dendreon) for prostate cancer [58].
Importantly, the baculovirus expression system is not limited only to cultured cells. Insect larvae or pupae can be used for protein production. In the context of edible vaccines using insect larvae or pupae, silkworm Bombyx mori larvae or pupae have been commercially used for the production of recombinant proteins and also as a feasible delivery system for the vaccine [59, 60]. As mentioned above, the baculovirus-silkworm expression system is able to perform cotranslational and posttranslational modifications and also able to produce large amount and multiple proteins. Moreover, since baculovirus is unable to replicate in vertebral animals, it can be considered a GRAS. Furthermore, the presence of protease inhibitors and biocapsule-like fat in the silkworms may protect recombinant proteins from enzymatic digestion in the GIT [23, 61].
Several vaccine prototypes are currently under evaluation, and strong systemic immune protective responses support the use of silkworm as a mucosal vaccine vector, as shown, for example, by high immunogenicity in mice of the urease B subunit of Helicobacter pylori produced in silkworm [60, 62]. While the data collected so far support the possible use of baculovirus-silkworm vaccines as a promising edible vaccine platform, it is only approved for food ingestion in a few Asian countries.”
https://www.hindawi.com/journals/jir/2019/8303648/
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.